Welcome to our dedicated page for PureTech Health plc SEC filings (Ticker: PRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PureTech Health plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PureTech Health plc's regulatory disclosures and financial reporting.
PureTech Health plc reported a leadership change, announcing that Robert Lyne has been appointed as its Chief Executive Officer. This update comes through a Form 6-K submission that notes the company issued a press release titled “PureTech Appoints Robert Lyne as Chief Executive Officer” on December 18, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains further details about Lyne’s new role and the company’s leadership plans.
PureTech Health plc submitted a Form 6-K as a foreign private issuer to provide investors with its half-year information package. The company furnished a press release summarizing its half-year report, an interim management report and financial review for the six months ended June 30, 2025 and 2024, and unaudited condensed consolidated financial statements covering the same periods and as of December 31, 2024. These materials give a detailed update on the company’s mid-year performance and financial position, but the specific financial results are contained in the attached exhibits rather than in this cover document.
Citigroup and several of its subsidiaries report a collective beneficial ownership of 13,220,374 ordinary shares of PureTech Health plc, representing 5.5% of the class. The filing names five Citigroup reporting persons and discloses that the position carries shared voting power and shared dispositive power; no sole voting or dispositive authority is reported.
The statement indicates the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also describes the chain of ownership among the Citigroup entities that hold the position.